chromium-51 labelled red cells in patients with ulcerative colitis (n= 12), Crohn's disease (n=15), and NSAID induced enteropathy (n=34). Intestinal inflammation and blood loss correlated significantly (Spearman) in patients with ulcerative colitis (20.3% v 6-5 ml/d (median) r: 0*85, p<0001) and NSAD enteropathy (1.6% v 19 mlld, r: 0-60, p<0-01) but not in Crohn's disease (17.0% v 2-1 ml/d, r: 0-38, p>Ol). For a given indium-ill excretion, patients with ulcerative colitis had significantly greater (p<001) blood loss than patients with Crohn's disease. These results suggest that the predominant site of neutrophil chemoattractants may be within the mucosa in ulcerative colitis and NSAID enteropathy and within the lumen in Crohn's disease. (Gut 1993; 34: 1535 -1538 The study of humoral and cellular immunopathogenesis of inflammatory bowel disease has received much interest.' The most characteristic feature of clinical relapse is the increased flux of neutrophils into the intestine.' Understanding the movement of neutrophils and the mechanisms through which they mediate tissue injury is fundamental to elucidating the pathogenesis of relapse.
Although controversial,78 it now seems likely that the striking 'in vitro' findings9 '°of reduced neutrophil mobilisation and altered function in patients with inflammatory bowel disease are not intrinsic to the cell but reflect neutrophil conditioning by different inflammatory milieu. Study of indium-l 1 labelled neutrophils shows close similarities between ulcerative colitis and Crohn's disease in respect of the quantity and kinetics of neutrophil migration from blood to lumen across the intestinal mucosa. 4 The question then arises as to the site and nature of the neutrophil chemoattractant. The latter has been extensively studied by Stenson," who suggested a two stage pathogenic framework for inflammatory bowel disease. He proposes that there is an as yet unknown triggering event which initiates an early neutrophil influx. Subsequent to this there is an amplified second phase of neutrophil chemotaxis which is much greater than the original. There is compelling evidence to suggest that the second amplification stage is mediated by leukotriene B4, a lipo-oxygenase product released by the neutrophils themselves.' 113 It is clear that whatever the primary or secondary chemoattractant is the neutrophils destined for it will respond in a predictable fashion. 14 IS On contact with the chemoattractant they form oxygen reactive species and there is release of lysosomal enzymes after phagocytosis. Both of these mechanisms may destroy the chemoattractant but will also cause unavoidable nonspecific damage in the immediate vicinity of the neutrophil. 14 15 The site of neutrophil chemoattractants may therefore be an important determinator of the secondary damage (as assessed by blood or protein loss) caused by neutrophils. This is particularly well demonstrated in the experimental animal where the emigration of neutrophils through the intestinal mucosa in response to a luminal chemoattractant does not cause tissue damage while intracutaneous inoculation of the same substance does. '6 In an attempt to localise, in vivo, the site of neutrophil chemoattractants in patients with ulcerative colitis and Crohn's disease, we used a dual isotope method to quantitate simultaneously intestinal inflammation and blood loss. We argued from the above that the two should correlate closely if the neutrophils are seeking a mucosal chemoattractant, less so if the chemoattractant is in the lumen, in which case the inflammation should be disproportionally greater than the blood loss. Patients on nonsteroidal anti-inflammatory drugs (NSAID) acted as a control group. '7 18 There is some evidence to suggest that the neutrophil chemoattractant in NSAID enteropathy may be a metronidazole sensitive microbe. '9 Subjects and methods Patients were recruited from gastroenterology and rheumatology outpatient clinics at Northwick Park Hospital. All 18 -70 years; 13 were on no treatment, one on 10 mg prednisolone and one on sulphasalazine) were studied. There were no significant differences in haemoglobin; white cell and platelet counts; erythrocyte sedimentation rate; or clinical disease activity20 between patients with ulcerative colitis and those with Crohn's disease. After the indium-ill and 51-chromium excretion studies all patients had a full colonoscopy or double contrast barium enema to confirm the diagnosis and to evaluate the extent of disease.
PATIENTS WITH RHEUMATOID ARTHRITIS
Thirty four patients with rheumatoid arthritis were studied. The patients had been on treatment for more than six months and although the type of NSAID varied, all had been established on one drug continuously for over six weeks. Twenty patients were on concomitant, second line agents (nine colchinine, six gold im, five penicillamine); but we have previously shown that these drugs do not affect the frequency or severity of the small intestinal inflammation caused by NSAIDs. 17 18 
INDIUM LABELLING STUDIES
An indwelling catheter was placed in an anticubital vein. Six millilitres of blood were drawn into a syringe containing I1 ml of acid citrate dextrose (National Institutes of Health formula A), dispensed into two sterile polythene tubes, and allowed to sediment for one hour at room temperature. The supernatant was removed and centrifuged at 100 g for five minutes. The resultant supernatant was removed immediately and respun at 300 g to yield a cell free plasma. The pellet from the 100 g centrifugation was resuspended and incubated for 10 minutes at room temperature in 0-1 HEPES saline buffer (pH 7 4) containing 20 Figure 2 shows that there is a;, 3537 Luminal factors also seem to be important in the recurrence of disease after surgery.38 39 The precise nature of neutrophil chemoattractants in these disorders is unknown and they could be of a diverse nature including microbial, chemical (including prostanoids) or indeed in ulcerative colitis the damaged colonocytes themselves.
In conclusion, the acute inflammatory infiltrate and bleeding go hand in hand in active ulcerative colitis and in patients taking NSAIDs, suggesting that the main neutrophil chemoattractant(s) is within the mucosa. In Crohn's disease there is disproportionally greater inflammation than blood loss and the lack of correlation between the two suggests that the predominant site of the chemoattractants is within the gut lumen.
Thanks to Drs M J Gumpel and A J Levi for allowing us to study patients attending their outpatient clinics.
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